A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-02. Anything still debated is marked as such rather than presented as settled.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
== Adverse effects == The most common side effects include headache, fever, fall, cough, vomiting, abdominal pain, cold symptoms (nasopharyngitis) and nausea. In animal studies, no significant changes were seen in the male reproductive system of monkeys and mice following weekly subcutaneous administration. According to the reports obtained from the clinical trials, pain at the site of intravenous administration, back pain, oropharyngeal pain, sprain in ligaments, diarrhea, dizziness, contusion, flu, ear infection, rhinitis, skin abrasion, tachycardia, and constipation occurred at an elevated frequency in the treatment group, as compared to their placebo counterparts. Hypersensitivity reactions, including rash, fever, itching, hives, skin irritation (dermatitis) and skin peeling (exfoliation), have occurred in people who were treated with golodirsen. Renal toxicity was observed in animals who received golodirsen. Although renal toxicity was not observed in the clinical studies with golodirsen, potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Renal function should be monitored in those taking golodirsen.
=== Radionuclides with half-lives of 104 years to 108 years === Ordered by half-life. Some of these are known to have been present in the early Solar System (marked "ESS", meaning the first few million years of the Solar System's history) from an excess of their decay products.
Assassinian Jingi (アサシン星人ジンギ, Asashin Seijin Jingi): A self-centered scorpion-themed assassin from Planet Assassin who has a chain on his head capable of sending targets to another dimension and who considers his skills far beyond that of typical killers, becoming murderously violent whenever someone questions or insults him. He kills indiscriminately until the Dekarangers confront him. He pilots a Kaijuki called Ultimate Evil 2 (アルティメットイビル2, Arutimetto Ibiru Tsū) in retaliation, but is deleted by the Deka Wing Cannon. Jingi is voiced by Minami Takayama (高山 みなみ, Takayama Minami). Sumasuleenian Nikaradar (スマスリーナ星人ニカレーダ, Sumasurīna Seijin Nikarēda): A spiky squid-themed criminal, and breeder of alien monsters called Browgoul, from Planet Sumasuleen who is capable of disguising himself as others and is willing to sacrifice countless worlds to ensure his pets' existence. After arriving on Earth, he murdered a professor and fed his corpse to a hatched Browgoul before assuming the deceased's identity to redirect a meteor towards Earth. However, the Dekarangers discover his true identity and delete him via their S.W.A.T. Modes. Nikaradar is voiced by Hiroyuki Shibamoto (柴本 浩行, Shibamoto Hiroyuki). Bokudenian Biskes (ボクデン星人ビスケス, Bokuden Seijin Bisukesu): A reckless fish-themed criminal and former friend of Kruger's from Planet Bokuden who previously trained with him, is charged with illegally challenging 999 fighters in duels to the death, and possesses the Sword Altair (ソード・アルタイル, Sōdo Arutairu), with which he can perform the Altair Slash (アルタイルスラッシュ, Arutairu Surasshu) attack.
== Corporate structure == TikTok Ltd was incorporated in the Cayman Islands in the Caribbean and is based in both Singapore and Los Angeles. It owns entities which are based respectively in Australia (which also runs the New Zealand business), United Kingdom (also owns subsidiaries in the European Union), and Singapore (owns operations in Southeast Asia and India). A spin-off company, TikTok USDS Joint Venture LLC was formed on 22 January 2026 to handle TikTok and other ByteDance properties in the United States. Oracle Corporation, MGX Fund Management Limited, Silver Lake each hold a 15% stake, ByteDance holds a 19.9% stake, and the remaining 35.1% is shared between Dell Technologies founder Michael Dell and Vastmere Strategic Investments. Its parent company, Beijing-based ByteDance, is owned by founders and Chinese investors, other global investors, and employees. One of ByteDance's main domestic subsidiaries is owned by Chinese state funds and entities through a 1% golden share. Employees have reported that multiple overlaps exist between TikTok and ByteDance in terms of personnel management and product development. TikTok says that since 2020, its US-based CEO is responsible for making important decisions, and has downplayed its China connection.
== Metabolism == In mammals, 1,6-dichloro-1,6-dideoxyfructose is metabolized in the liver and erythrocytes by a reaction with glutathione that replaces one of the chlorine atoms, forming 6-chlorofructos-1-yl glutathione (or chlorofructosyl glutathione).
Sources: en.wikipedia.org
== Sites of synthesis == Leptin is produced primarily in the adipocytes of white adipose tissue. It also is produced by brown adipose tissue, placenta (syncytiotrophoblasts), ovaries, skeletal muscle, stomach (the lower part of the fundic glands), mammary epithelial cells, bone marrow, gastric chief cells, and P/D1 cells.
== References == Butler, Rohan, MA., Bury, J.P.T., MA., & Lambert M.E., MA., editors, Documents on British Foreign Policy 1919–1939, 1st Series, Her Majesty's Stationery Office, London, 1960, vol. x, Chapter VIII, "The Plebiscites in Allenstein and Marienwerder January 21 – September 29, 1920" Keynes, John Maynard. A Revision of the Treaty: Being a Sequel to The Economic Consequences of the Peace, Harcourt, Brace, 1922 Kossert, Andreas. Masuren: Ostpreussens vergessener Süden, ISBN 3-570-55006-0 (in German) Mayer, S. L., MA. History of the First World War – Plebiscites:Self Determination in Action, Peter Young, MA., editor, BPC Publishing Ltd., UK., 1971. Rhode, Gotthold. Die Ostgebiete des Deutschen Reiches, Holzner-Verlag Würzburg, 1956. Tooley, T. Hunt. National Identity and Weimar Germany: Upper Silesia and the Eastern Border, 1918–1922, U of Nebraska Press, 1997, ISBN 0-8032-4429-0 Topolski, Jerzy. An Outline History of Poland, Interpress, 1986, ISBN 83-223-2118-X Wambaugh, Sarah. Plebiscites since the World War, Washington DC, 1933. I pp 99–141; II pp 48–107 Williamson, David G. The British in Germany 1918–1930, Oxford, 1991, ISBN 0-85496-584-X
== Mechanism of action == Lubiprostone is a bicyclic fatty acid derived from prostaglandin E1 that acts by specifically activating ClC-2 chloride channels on the apical aspect of gastrointestinal epithelial cells, producing a chloride-rich fluid secretion. These secretions soften the stool, increase intestinal transit and decrease gastric emptying, and promote spontaneous bowel movements.
== Biochemical context == Most are accompanied by α-ketoglutarate α-decarboxylation caused by dehydrogenation of hydroxyl carboxylic acids such as carbonyl carboxylic malic acid, isocitric acid, etc. Pyruvate is susceptible to oxidative decarboxylation to deliver the equivalent of the acetyl anion:
Milatović was sworn in on 20 May 2023 in the Parliament of Montenegro in Podgorica instead of the traditional inauguration place of Cetinje. His inauguration was attended by numerous Balkan leaders such as Aleksandar Vučić, Zoran Milanović, Željko Komšić, Željka Cvijanović, Denis Bećirović, Vjosa Osmani, Bajram Begaj, and Galab Donev. Milatović was also congratulated by Pope Francis. In June 2023, Milatović stated he expected Montenegro to join the European Union by 2027 or 2028. In August 2023, he met with Ukrainian president Volodymyr Zelenskyy in Athens, stating that Montenegro "openly and strongly condemns Russia's unprovoked aggression against Ukraine." On 28 August 2023, Milatović said that the "winning energy" after his presidential election had been "shattered" by the disagreements over the new government formation, appealing to the prime minister-designate Spajič and everyone participating in the consultations on the formation of the new government to make the process "more transparent and in accordance with the electoral will". On 24 February 2024, Milatović announced he would be leaving PES!, following a split with Spajić.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.